Real-world study confirms Entyvio's safety for ulcerative colitis patients
NCT ID NCT03824561
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This study looked at over 1,100 people with moderate to severe ulcerative colitis who were given Entyvio (vedolizumab) as part of their regular care. The goal was to see how safe and effective the drug is over the long term. Researchers tracked side effects and how well patients responded after three doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.